CIK 0000784199 · Large accelerated filer
ARTIVION, INC.
Sign in to watch- Ticker
- AORT
- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 592417093
- Phone
- 7704193355
- Business address
- 1655 ROBERTS BOULEVARD N W, KENNESAW, GA, 30144
- Former names
- CRYOLIFE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,529,843
- in 3 filings
Net −$2,529,843. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-12 | Davis John E Chief Commercial Officer | Option exercise | +10,802 | $26.24 | $283K | 219,580 |
| 2025-08-12 | Davis John E Chief Commercial Officer | Sale | −10,802 | $43.67 | $472K | 208,778 |
| 2025-08-12 | Davis John E Chief Commercial Officer | Option exercise · Stock Options (Right to buy) | −10,802 | 0 | ||
| 2025-08-12 | Holloway Jean F SVP, General Counsel | Option exercise | +16,975 | $26.24 | $445K | 195,485 |
| 2025-08-12 | Holloway Jean F SVP, General Counsel | Sale | −16,975 | $43.01 | $730K | 178,510 |
| 2025-08-12 | Holloway Jean F SVP, General Counsel | Sale | −6,381 | $43.02 | $274K | 172,129 |
| 2025-08-12 | Holloway Jean F SVP, General Counsel | Option exercise · Stock Option(Right to Buy) | −16,975 | 0 | ||
| 2025-08-08 | Horton Amy VP, Chief Accounting Officer | Option exercise 10b5-1 | +7,992 | $29.62 | $237K | 154,643 |
| 2025-08-08 | Horton Amy VP, Chief Accounting Officer | Sale 10b5-1 | −7,992 | $38.49 | $308K | 146,651 |
| 2025-08-08 | Horton Amy VP, Chief Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,992 | 0 | ||
| 2025-06-17 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale 10b5-1 | −13,764 | $29.50 | $406K | 65,436 |
| 2025-06-17 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale 10b5-1 | −1,236 | $29.50 | $36K | 64,200 |
| 2025-06-13 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale 10b5-1 | −8,747 | $28.46 | $249K | 96,585 |
| 2025-06-13 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale 10b5-1 | −1,253 | $28.47 | $36K | 95,332 |
| 2025-06-13 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale 10b5-1 | −14,306 | $28.42 | $407K | 81,026 |
| 2025-06-13 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale 10b5-1 | −1,826 | $28.43 | $52K | 79,200 |
| 2025-05-27 | Holloway Jean F SVP, General Counsel | Sale | −8,748 | $29.00 | $254K | 178,510 |
| 2025-05-23 | SEMEDO ANTHONY B. Director | Sale | −2,600 | $28.47 | $74K | 39,384 |
| 2025-05-23 | SEMEDO ANTHONY B. Director | Sale | −2,600 | $28.47 | $74K | 33,059 |
| 2025-05-22 | SEMEDO ANTHONY B. Director | Grant or award | +6,325 | 41,984 |
Page 7 of 11 · 201 trades